Poster Proofs CONCLUSION: Use of perioperative blood transfusion varied among surgeons. However, there was no evidence for surgeonlevel variation in potentially unnecessary perioperative transfusion. Transfusions were significantly associated with higher risk of perioperative infections and postoperative readmissions. These findings emphasize the importance of standardizing transfusion practices with the goal of minimizing unnecessary transfusions and their potential negative consequences. 
PURPOSE:
Seeding the tissue-engineered constructs with endothelial cells (ECs) may accelerate neovascularization and prevent the resorption of the constructs. However, the use of autologous ECs is hampered by the need to harvest a blood vessel from the patient and the technical challenges of EC culture. Our aim in this study is to determine whether human adipose-derived stem cells (ASCs) can be an alternative EC source for clinical tissue engineering applications.
METHODS:
We harvested human ASCs from adipose tissue samples via enzymatic digestion and characterized them with flow cytometry and tri-lineage differentiation. We fed ASCs from PIII-V with EGM-2MV endothelial cell differentiation medium (Lonza Pharmaceuticals, Basel, Switzerland) for up to three weeks. We harvested the cells after 1, 2 and 3 weeks, and evaluated endothelial differentiation with Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), flow cytometry, and angiogenic sprouting assays.
RESULTS:
ASCs were CD 90+, CD 44+, and CD 31-prior to differentiation. They differentiated into adipogenic, osteogenic, and chondrogenic lineages as detected by Oil Red O, Alizarin red and Alcian blue staining, respectively. The expression of EC specific genes in ASCs made a peak at the second week of differentiation. The fold changes in expression of CD31, vascular endothelial growth factor receptor-1, nitric oxide synthase, and von Willebrand Factor genes at week 2 were 0.4 ± 0.1, 34.7 ± 0.3, 2.03 ± 0.25 and 12.5 ± 0.3 respectively. The percentage of CD 31+ cells in total ASCs population as detected by flow cytometry was 0.2, 0.64, and 1.6 at weeks 1, 2, and 3, respectively. ASCs formed an average of 4.0 ± 0.4, 1.8 ± 0.6, and 0.7 ± 0.1 sprouts/bead at weeks 1, 2, and 3 of differentiation, respectively. Moreover, human ASCs derived ECs displayed enhanced sprouting capability as compared to human microvascular endothelial cells (p<0.05).
CONCLUSION:
Human ASCs have the potential to become a clinical source of ECs. Further refinement of the growth factor concentrations in the differentiation medium may increase the endothelial differentiation of human ASCs.
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Oxysterol as a Deterrent of Adipogenesis: in vitro and in vivo Studies
Reena Bakshi, MD, Akishige Hokugo, DDS, PhD, Luis Segovia, MD, Situo Zhou, MD, Kameron Rezzadeh, MD, Patricia Zuk, PhD, Reza Jarrahy, MD UCLA, Los Angeles, CA PURPOSE: Therapeutic options for obesity and related diseases are limited and often carry significant consequences. New therapies targeting key stages in adipocyte commitment and maturation have shown clinical promise. One potential strategy is to use oxysterols-naturally occurring bioactive molecules-to influence adipose tissue metabolism. To determine if this feature might function as an anti-adipogenic agent, a series of in vitro studies was designed to determine if one isoform of oxysterol, Oxy133, might influence the differentiation process of already committed premature adipose cells. We also examined the in vivo effects of Oxy133 on adipogenesis with adipose-derived stem cells grafting in a mouse model.
METHODS:
Mouse preadipocyte, 3T3-L1 cell lines was cultured with basal growth medium (GM). After cells reached confluency, they were re-seeded on multi-well plates. Cells were treated with conventional adipogenic medium (AM) containing DMEM, 10% FBS, penicillin-streptomycin with isobutyl methylxanthine, dexamethasone, and insulin with or without Oxy133. A negative control using GM alone was also included. Measuring differentiation specific gene expressions (PPARγ, CEBP, GPD, and Adiposin) tested for active adipogenesis, and an Oil Red O stain established mature adipocyte functionality and morphology. For the in vivo study, human adipose-derived stem cells (hASC) were cultured and maintained until 90% confluence. Cells were then cultured in adipogenic medium (control) or treated with adipogenic medium with Oxy133. We subsequently collected and injected the cells into the subcutaneous tissue on the scalp of nude mice. After 12 weeks, the specimens were harvested for histologic analysis.
RESULTS:
Expression of adipogenic differentiation specific genes were reduced in cells exposed to the Oxy133, in contrast to positive control groups. Functionality and morphology of mature adipocytes attenuated in the Oxy133-treated cells. Mice injected with hASCs treated with Oxy133 demonstrated significantly decreased adipose tissue as compared to control animals after 12 weeks.
CONCLUSIONS:
Our studies demonstrated the ability of Oxy133 to impede differentiation of preadipocytes into mature functional adipocytes in vitro. Oxy133 also impeded adipogenesis of hASCS in vivo. Oxy133 represents a potentially viable therapy for anti-fat agent in obesity.
